2020年5月25日 · Background: LAM-002 is a selective inhibitor of PIKfyve that disrupts lysosomal homeostasis, inducing cytotoxicity in B-cell lymphoma models as monotherapy or with anti-CD20 or anti-PDL1 antibodies (Gayle et al., Blood 2017;129 (13):1768). Methods: In this study, patients received LAM-002 orally 2-3 times per day (BID or TID) in a 3+3 escalation.

Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).

2014 ASCO Annual Meeting A patient-derived xenograft (PDX) platform to optimize omics-driven precision medicine in bladder cancer . First Author: Chong-xian Pan

2025年3月7日 · Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

Welcome to the new ASCO.org! ASCO.org has a new look and feel, making it easier than ever to find premier oncology research from ASCO Meetings and Journals, and offering customized recommendations for signed-in users. Explore the site using the …

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Take advantage of early registration rates and secure your spot at the global oncology event of 2025! Don’t miss out—the ASCO Annual Meeting is The Place to Be.

2020年1月30日 · AI Therapeutics ‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence -based platform — called Guardian Angel — as a possible treatment for amyotrophic lateral sclerosis (ALS). Researchers from AI have already tested and confirmed LAM-002’s therapeutic potential in an ALS context.

2023年5月31日 · Deep learning AI algorithms are used to identify the gastric cancer signature. Results from testing and validation of the identified routine blood signature using a Big Clinical Data cohort are reported. Methods: This is a territory-wide healthcare database study using data from Hong Kong Hospital Authority data collaboration laboratory.

American Society of Clinical Oncology - Photo Gallery